Article Text

Download PDFPDF

Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5
  1. M. A. Bookman*,
  2. B. E. Greer and
  3. R. F. Ozols*
  1. * Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA
  2. Division of Gynecologic Oncology, University of Washington School of Medicine, Seattle, WA
  1. Address correspondence and reprint requests to: Michael A. Bookman, MD, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA. Email: ma_bookman{at}fccc.edu
  1. Presented in part as ‘Carboplatin–Paclitaxel versus Cisplatin-Paclitaxel and Update on GOG0182-ICON5’ at the 4th International Symposium, Advanced Ovarian Cancer: Optimal Therapy, Update, Valencia, Spain (28 February 2003).

Abstract

Mature results from GOG158 have clearly established carboplatin and paclitaxel as an effective and well-tolerated standard regimen, providing a basis for the reference arm in GOG0182-ICON5, an ongoing multiarmed phase III trial of the Gynecologic Cancer InterGroup (GCIG) evaluating the incorporation of newer cytotoxic agents. Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5.

  • carboplatin
  • ovarian cancer
  • paclitaxel
  • second-look

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.